Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis
- PMID: 19157420
- DOI: 10.1016/j.jns.2008.12.019
Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis
Abstract
Background: Cognitive impairment is frequent in multiple sclerosis (MS). Tissue-specific atrophy measures have been shown to correlate with cognitive performance in several studies. Voxel-based morphometry (VBM) aims to identify regional differences in the local composition of brain tissue and makes possible to correlate these findings with cognitive impairment patterns.
Aim: To investigate the associations between cognitive impairment in MS and tissue-specific atrophy and regional distribution of grey matter.
Method: 15 patients with MS and cognitive impairment were included. Demographic (age and years of schooling) and clinical (Multiple Sclerosis Functional Composite-MSFC and subtests, Expanded Disability Status Scale-EDSS, disease duration) variables were recorded and neuropsychological assessments performed (Trail Making Test A and B-TMTA and B, Symbol Digit Modalities Test-SDMT, Digit Span Test-DST and Rey's Auditory Verbal Learning Test Delayed Recall-RAVLT-DR). Magnetic resonance (MR) 3D sequences (MPRAGE) were performed on all subjects and tissue-specific volumes (SIENAx and SPM2 software) and VBM grey matter probability maps (SPM2) were obtained.
Results: Moderate correlations were obtained between tissue volumes obtained with SPM2 and SIENAx. Using SIENAx moderate correlations were obtained between normalised brain volume (NBV) and disease duration (rho=-0.575, p=0.025) and RAVLT-DR (rho=0.518, p=0.048). Using SPM2 moderate correlations were obtained between white matter and brain parenchymal fractions (WMF and BPF) and RAVLT-DR (rho=0.572 and 0.539, p=0.026 and 0.038), between grey matter fraction (GMF) and Z scores on the Paced Auditory Serial Addition Test (PASAT) (rho=0.570, p=0.026), and between BPF and disease duration (rho=-0.6, p=0.018). Significant correlations were observed only between regional grey matter probability maps and grey matter (and to a much lesser extent white matter) volumes from SPM2.
Conclusion: Quantitative tissue-specific atrophy measures may display better correlations with patients' variables than regional grey matter atrophy distribution obtained using VBM methodology. These results should be confirmed in larger samples.
Similar articles
-
Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis.Mult Scler. 2007 Jul;13(6):722-30. doi: 10.1177/1352458507075592. Epub 2007 Mar 15. Mult Scler. 2007. PMID: 17613599
-
Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.Mult Scler. 2008 Nov;14(9):1242-9. doi: 10.1177/1352458508094398. Epub 2008 Jul 24. Mult Scler. 2008. PMID: 18653737
-
Quantitative diffusion weighted imaging measures in patients with multiple sclerosis.Neuroimage. 2007 Jul 1;36(3):746-54. doi: 10.1016/j.neuroimage.2007.03.056. Epub 2007 Apr 10. Neuroimage. 2007. PMID: 17498974
-
Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations.J Clin Neurosci. 2007 Oct;14(10):919-27. doi: 10.1016/j.jocn.2007.02.006. Epub 2007 Jul 30. J Clin Neurosci. 2007. PMID: 17659875 Review.
-
Cortical pathology and cognitive impairment in multiple sclerosis.Expert Rev Neurother. 2011 Mar;11(3):425-32. doi: 10.1586/ern.10.155. Expert Rev Neurother. 2011. PMID: 21375447 Review.
Cited by
-
The Contribution of Various MRI Parameters to Clinical and Cognitive Disability in Multiple Sclerosis.Front Neurol. 2019 Jan 23;9:1172. doi: 10.3389/fneur.2018.01172. eCollection 2018. Front Neurol. 2019. PMID: 30728801 Free PMC article.
-
Assessing the correlation between grey and white matter damage with motor and cognitive impairment in multiple sclerosis patients.PLoS One. 2013 May 16;8(5):e63250. doi: 10.1371/journal.pone.0063250. Print 2013. PLoS One. 2013. PMID: 23696802 Free PMC article.
-
Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine.J Neurol. 2012 Mar;259(3):505-14. doi: 10.1007/s00415-011-6212-9. Epub 2011 Sep 9. J Neurol. 2012. PMID: 21904901 Clinical Trial.
-
Depressive symptoms, anxiety and cognitive impairment: emerging evidence in multiple sclerosis.Transl Psychiatry. 2023 Jul 19;13(1):264. doi: 10.1038/s41398-023-02555-7. Transl Psychiatry. 2023. PMID: 37468462 Free PMC article. Review.
-
Identification of Cortical and Subcortical Correlates of Cognitive Performance in Multiple Sclerosis Using Voxel-Based Morphometry.Front Neurol. 2018 Oct 29;9:920. doi: 10.3389/fneur.2018.00920. eCollection 2018. Front Neurol. 2018. PMID: 30420834 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical